

*" Studies on the Potential Chemomodulatory Effects  
of a Honey Bee Product in Prostate Cells "*

A thesis submitted for the partial fulfillment of the requirements of Ph.D. Degree in  
Pharmaceutical sciences (Pharmacology and Toxicology)

By

**Mai Fathy Bayomi Tolba**

B.Sc. Pharmacy (2006)  
Faculty of Pharmacy, Ain Shams University

M.Sc. Pharmacology and Toxicology (2011)  
Faculty of Pharmacy, Ain Shams University

Supervisors

**Prof. Dr. Ashraf B. Abdel-Naim**

Professor of Pharmacology and Toxicology  
Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

**Prof. Dr. Amani Emam Khalifa**

Professor of Pharmacology and Toxicology  
Faculty of Pharmacy, Ain Shams University, Cairo, Egypt  
Seconded to the Holding Company for Biological Products and Vaccines  
as the Consultant of the Chairman

**Prof. Dr. Sherif Z. Abdel-Rahman**

Associate Professor, Department of Obstetrics and Gynecology, The University of Texas Medical  
Branch, Galveston, Texas, USA

**Dr. Samar Azab**

Lecturer of Pharmacology and Toxicology  
Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

Department of Pharmacology and Toxicology, Faculty of Pharmacy,  
Ain Shams University, 2013

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَأَوْحَىٰ رَبُّكَ إِلَى النَّحْلِ أَنْ اتَّخِذِي مِنَ الْجِبَالِ بُيُوتًا وَمِنَ الشَّجَرِ وَمِمَّا  
يَعْرِشُونَ (٦٨) ثُمَّ كُلِي مِنْ كُلِّ الثَّمَرَاتِ فَاسْلُكِي سُبُلَ رَبِّكِ ذُلًّا يَخْرُجُ  
مِنْ بُطُونِهَا شَرَابٌ مُخْتَلِفٌ أَلْوَانُهُ فِيهِ شِفَاءٌ لِلنَّاسِ إِنَّ فِي ذَلِكَ  
لَآيَةً لِّقَوْمٍ يَتَفَكَّرُونَ

سورة النحل (٦٩)

صدق الله العظيم

*“I dedicate this thesis to  
my dear parents. Without their support, patience,  
understanding and love, the completion of this  
work wouldn't have been possible”*

## *Acknowledgements*

In the name of Allah, The Most Gracious and The Most Merciful. Peace and blessings be upon our Prophet Mohammad and his good followers till the Day of Judgment.

At the beginning, I would like to express my sincere thanks and gratitude to my supervisors: Prof. Dr. Ashraf B. Abdel-Naim, Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain-Shams University for being so generous with his knowledge and being so supportive in all aspects. I learned a lot from him. I am so grateful to him for his sincere efforts and guidance through the entire work. I thank him also for establishing cell culture laboratory and western blotting facility in our Department. This thesis is the first one accomplished in this new Laboratory.

I would like to extend my appreciation and thankfulness to my supervisor, Prof. Dr. Amani Emam Khalifa, Professor of Pharmacology, and Toxicology Faculty of Pharmacy, Ain-Shams University, for her sincere help, advice, and wholehearted support through the entire way of accomplishing this work.

Sincere appreciation is extended to my supervisor, Prof. Dr. Sherif Z. Abdel-Rahman, Associate Professor, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, for his sincere help, co-operation, advice and support through the period of my work in the University of Texas Medical Branch.

I would like to thank my supervisor, Dr. Samar S. Azab, Lecturer of Pharmacology, and Toxicology Faculty of Pharmacy, Ain-Shams University, for her kind help.

I would like to thank Prof. Dr. Abdel-Hamid El-Shamy, Professor of Pharmaceutics and Drug Technology, Faculty of Pharmacy, Ain Shams University, for all what I learned from him both on the scientific and human aspects. May Allah Bless his soul and grant him Al-Gannah.

Special thanks to, Prof. Dr. Samia Showman, Cancer Biology Department, National Cancer Institute, for her generous gift of prostate cell lines.

Special thanks to my colleague, Dr. Ahmed Esmat Lecturer of Pharmacology, and Toxicology Faculty of Pharmacy, Ain-Shams University for helping me to learn western blotting analysis.

Special appreciation is offered to my colleague, Dr. Hany Mostafa, Department of Pharmacology, Faculty of Pharmacy, Beni-Suef University, for his generous collaborations with prostate cell lines and antibodies as well as his sincere help in calculus analysis.

I would like to thank my colleagues in the Faculty of Pharmacy, Ain Shams University and the University of Texas Medical Branch for their kind help, encouragement and support.

I would like to thank my colleague, Dr. Mohamed El-Sayed, Cancer biology Department, National Cancer Institute, and my students, Mohamed Hussein and Al-Siddeg Kamal for their kind help. I would like to thank my friend Maisaa El-Sayed for her support and encouragement.

I would like to express my gratitude and thankfulness to my dear family: my father, my mother, my dear siblings Mohammed and Mennat-Allah for giving me all the love and wholehearted support to continue.

*Mai Fathy*

## Supervision Committee

**Prof. Dr. Ashraf B. Abdel-Naim**

Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

**Prof. Dr. Amani E. Khalifa**

Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Seconded to the Holding Company for Biological Products and Vaccines as the Consultant of the Chairman

**Prof. Dr. Sherif Z. Abdel-Rahman**

Associate Professor, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, Texas, USA

**Dr. Samar S. Azab**

Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

## Approval Sheet

### " Studies on the Potential Chemomodulatory Effects of a Honey Bee Product in Prostate Cells "

Candidate name:

***Mai Fathy Bayomi Tolba***  
*Ph. D. Degree in Pharmaceutical sciences*  
*(Pharmacology and Toxicology)*

#### Approved by the Committee in Charge:

**1- Prof. Dr.Mohamed Mohey El-Deen Atta** .....

Professor of Pharmacology and Toxicology  
and Dean of the Faculty of Pharmacy, British  
University in Egypt (BUE)

**2- Prof. Dr.Amani Emam Khalifa** .....

Professor of Pharmacology and Toxicology  
Faculty of Pharmacy, Ain Shams University  
and Seconded to the Holding Company for  
Biological Products and Vaccines as the  
Consultant of the Chairman

**3-Prof. Dr.Gouda Kamel Abdel-Bary** .....

Professor of Pharmacology and Toxicology  
and Vice-Dean, Faculty of Pharmacy, Azhar  
University

**Date: 24-9-2013**

## *Table of contents*

Abstract	i
List of Abbreviations	iii
List of Tables	v
List of Figures	vi
Aim of the work	vii
Introduction	1
Materials and Methods	77
A) Design of the Work	77
B) Materials	79
C) Methods	82
Cell culture	82
Cytotoxicity assay	82
Synergy analysis	83
DNA-Flow cytometry analysis	85
Immunocytochemistry	86
Annexin V-FITC apoptosis assay	87
Reverse transcription-PCR	89
Western blot analysis Bax/Bcl-2	90
Caspase-3 activity assay	91
Western blot analysis ER- $\alpha$ and pER- $\alpha$	93
Testing AKT and ERK activation	94
Statistical Analysis	95
Results	96
Discussion	126
Summary & Conclusion	134
References	137
Arabic Summary	158

## *Abstract*

Evidence is growing for the beneficial role of selective estrogen receptor modulators (SERM) in prostate diseases. Caffeic acid phenethyl ester (CAPE) is a promising component of propolis that possesses SERM activity. The current study aimed at investigating the modulatory impact of CAPE on docetaxel (DOC) and paclitaxel (PTX) cytotoxicity in prostate cancer (PC) cells and exploring the possible underlying mechanisms for this chemomodulation. CAPE significantly increased DOC and PTX potency in PC-3, DU-145 and LNCaP PC cells. Combination index calculations showed synergistic interaction of CAPE/DOC and CAPE/PTX co-treatments in all the tested cell lines. Subsequent mechanistic studies in PC-3 cells indicated that cyclin D1 and c-myc were significantly reduced in the combined treatment groups with concurrent increase in p27<sup>kip</sup>. DNA-ploidy analysis indicated a significant increase in the percentage of cells in pre-G1 in CAPE/DOC and CAPE/PTX co-treatments. Decreased Bcl-2/Bax ratio together with increased caspase-3 activity and protein abundance were observed in the same groups. Estrogen receptor- $\beta$  (ER- $\beta$ ) and its downstream tumor suppressor forkhead box O1 (*FOXO-1*) levels were significantly elevated in CAPE and combination groups compared to DOC or PTX-alone. ER- $\alpha$  and insulin like growth factor-1 receptor (IGF-1R) protein abundance were reduced in the same groups. CAPE significantly reduced AKT, ERK and ER- $\alpha$  (Ser-167) phosphorylation in PC-3



cells. CAPE-induced inhibition of AKT phosphorylation was more prominent (1.7 folds higher) in cells expressing ER- $\alpha$  such as PC-3 compared to LNCaP. In conclusion, CAPE enhances the antiproliferative and cytotoxic effects of DOC and PTX in PC cells. This can be, at least partly, attributed to CAPE augmentation of DOC and PTX pro-apoptotic effects in addition to CAPE-induced alterations in ER- $\alpha$  and ER- $\beta$  abundance.

## *List of Abbreviations*

$\alpha$ -ERKO	ER- $\beta$ knockout transgenic mice
AD	Alzheimer's disease
AKT	Protein kinase B
ATRA	All-trans retinoic acid
AV	Atrio-ventricular
$\beta$ -ERKO	ER- $\beta$ knockout transgenic mice
BPH	Benign prostate hyperplasia
CAPE	Caffeic acid phenethyl ester
CAT	Catalase
CI	Combination index
COX-2	Cyclo-oxygenase-2
CRPC	Castration-resistant prostate cancer
CYP19	Aromatase
DAB	3,3'-diaminobenzidine
DEN	Diethylnitrosamine
DES	Diethylstilbestrol
DHT	Dihydrotestosterone
DMF	Dimethyl formaldehyde
DMSO	Dimethyl sulfoxide
DOC	Docetaxel
DPPH	2,2-Diphenyl-1-picrylhydrazyl
DRI	Dose reduction index
E2	Estradiol, Estrogens
ER- $\beta$	Estrogen receptor $\beta$
ER- $\alpha$	Estrogen receptor $\alpha$
ERK	p44/42 Mitogen activated protein kinase (MAPK)
FACS	Flourescence activated cell sorting (Flow cytometry)
FCAPE	Catechol-ring fluorinated derivative of CAPE
FOXO-1	Forkhead box O1
GPx	Glutathione peroxidase
GSH	Reduced glutathione
HO-1	Heme oxygenase-1
IC50	Half-maximal inhibitory concentration
ICAM-1	Intercellular adhesion molecule 1
IFN- $\gamma$	Interferon-gamma
IGF-1R	Insulin like growth factor-1 receptor
Ig-E	Immunoglobulin-E
IL-6	Interleukin -6

iNOS	Nitric oxide synthase
KLF5	Krüppel-like zink finger transcription factor5
LHRH	Luteinizing hormone resleasing hormone
LOX	5-Lipoxygenase
LPS	Lipopolysaccharide
MCP-1	Monocyte chemoattractant protein
MDA	Malone dialdehyde
MPO	Myeloperoxidase
MPT	Mitochondrial permeability transition
NF-kB	Nuclear factor (NF)-kB
PARP	Poly(ADP-ribose) polymerase
PBS	Phosphate buffesred saline
PC	Prostate cancer
PI	Propidium iodide
PI3K	Phosphoinositide-3-kinase
PIN	Prostatic intraepithelial neoplasia
pNA	p-nitroaniline
PSA	Prostate-specific antigen
PTEN	Phosphatase and tensin homolog deleted on chromosome 10
PTX	Paclitaxel
RAR- $\alpha$	Retinoic acid receptor - $\alpha$
SERMs	Selective estrogen receptor modulators
SOCS3	Suppressor of cytokine signaling-3
SOD	Superoxidase dismutase
SQM	Squamous metaplasia
SRB	Sulfarhodamine-B
STZ	Streptozotocin
T	Testosterone
TBST	Tris-buffered saline plus Tween-20
TLR4	Toll like receptor 4
TNF- $\alpha$	Tumor necrosis factor - $\alpha$
TRAMP	The transgenic adenocarcinoma of the mouse prostate
VLCFA	Very long chain fatty acids
X-ALD	X-linked adrenoleukodystrophy
XO	Xanthine oxidase

## *List of Tables*

<b>Table number</b>	<b>Title</b>	<b>Page</b>
Table 1	Synergy analysis for CAPE/DOC and CAPE/PTX combinations in PC-3 prostate cancer cells	100
Table 2	Synergy analysis for CAPE/DOC and CAPE/PTX combinations in DU-145 prostate cancer cells	101
Table 3	Synergy analysis for CAPE/DOC and CAPE/PTX combinations in LNCaP prostate cancer cells	102

## *List of Figures*

<b>Figure ID</b>	<b>Title</b>	<b>Page</b>
1	ER- $\alpha$ mediates the adverse actions of estrogen in the prostate.	22
2	ER- $\beta$ mediates the beneficial actions of estrogen in the prostate.	23
3	Chemical structure of DOC	29
4	Chemical structure of PTX	29
5	Polymerization of microtubules. Heterdimers of $\alpha$ - and $\beta$ -tubulin assemble to form a short microtubule nucleus.	32
6	Differential binding sites of microtubule inhibitors	34
7	Non linear pharmacokinetics of Taxol (PTX) versus linear pharmacokinetics of taxotere (DOC)	39
8	Molecular structure of CAPE	48
9	Components of pro-inflammatory signaling cascades as potential targets for	54
10	CAPE concentration-response plots in PC-3, DU-145, LNCaP and BPH-1 prostate cell lines. Data are means $\pm$ SD	98
11	Effect of CAPE on the cytotoxicity of DOC and PTX in PC-3, DU-145 and LNCaP prostate cancer cell lines after 72 h. Data are means $\pm$ SD (n=6)	99
12	Effect of CAPE on DNA-ploidy flow cytometric analysis of PC-3 cells treated with DOC or PTX.	104
13	CAPE effect on cell-cycle regulatory proteins in PC-3 cells treated with DOC or PTX for 24 h.	107
14	CAPE effect on the percentage of annexin-V FITC positive apoptotic in PC-3 cells treated with DOC or PTX	110
15	Effect of CAPE on the gene expression of apoptosis regulatory molecules Bax (A) and Bcl-2 (B) in PC-3 cells treated with DOC or PTX for 24 h.	113
16	Effect of CAPE on the protein expression of apoptosis regulatory molecules Bax and Bcl-2 in PC-3 cells treated with DOC or PTX for 24 h.	115
17	CAPE effect on caspase-3 protein abundance (A) and activity (B) in cells treated with DOC and PTX for 24 h	117
18	Effect of CAPE on the immunoreactivity of ER- $\beta$ (A) and its downstream tumor suppressor <i>FOXO-1</i> (B) in cells treated with DOC and PTX for 24 h using immunocytochemistry staining.	119
19	The effect of CAPE on the protein abundance of ER- $\alpha$ (A) and IGF-1R (B) in cells treated with DOC and PTX for 24 h using immunocytochemistry staining.	121
20	ER- $\alpha$ status of PC-3, DU-145 and LNCaP (A) and the effect of CAPE on pER- $\alpha$ (Ser 167) in PC-3 cells (B,C).	123
21	The effect of CAPE on AKT and ERK phosphorylation status in PC-3, DU-145 and LNCaP cell lines.	125

# *Aim of The Work*

Prostate cancer (PC) remains among the most frequently diagnosed solid tumors. It is considered a worldwide public health problem and is the first cause of death by cancer in men over 50 years of age (Jemal et al., 2010). Treatment options for castration-resistant PC (CRPC) are limited and are often associated with significant morbidity and mortality. The high incidence of recurrence and metastasis, as well as the refractory nature of CRPC to chemotherapy, make it one of the most challenging malignancies for therapeutic drug combination studies (Diaz *et al.*, 2004; Pinto *et al.*, 2009). Taxanes were emerged as a powerful class of chemotherapeutic agents that proved therapeutic efficacy in various types of solid tumors including breast and PC. Paclitaxel (PTX) is a natural product isolated from the Pacific yew (*Taxus brevifolia*). Docetaxel (DOC) is a semisynthetic taxane produced from the European yew (*Taxis baccata*). In PC, DOC has demonstrated a survival advantage and is set to become a frontline therapy in the management of castration-resistant PC (Mackler *et al.*, 2005; Magi-Galluzzi *et al.*, 2007). However, the use of high dose of taxanes is often associated with significant toxic reactions (Fossella *et al.*, 2000; Sewak *et al.*, 2010). Since low or moderate doses of taxanes have no significant antitumor activity in patients (Ryan *et al.*, 2002; Smith *et al.*, 2011), it is crucial to investigate ways to reduce their dose without affecting the antitumor activity. Accordingly, natural products with anti-cancer efficacy and least toxicity to normal tissues are suggested as possible candidates to be investigated for their synergistic efficacy in combination with the conventional chemotherapeutic agents (Agarwal 2000).

Caffeic acid phenethyl ester (CAPE) is a phenolic component of honey bee propolis that possesses a plethora of biological activities. Several studies reported its broad-spectrum anticancer activity *in vitro* and *in vivo* in multiple cancer models, as colon cancer (Xiang *et al.*, 2006), lung cancer (Chen *et al.*, 2004),